S-1/A: First Choice Healthcare Pivots to Wellness, Seeks $12M IPO

First Choice Healthcare Solutions, Inc. is undergoing a strategic pivot from its legacy orthopedic business to a national chain of primary care and wellness clinics, seeking to raise $12 million through a public offering of Series D Convertible Preferred Stock and warrants.

Summary

• The company is strategically pivoting from its historical orthopedic business model to developing a national chain of innovative primary care and wellness clinics, focusing on life improvement services (anti-aging, weight management, hormone replacement) and pharmacy services.
• All remaining legacy orthopedic and physical therapy services will be terminated upon the completion of the public offering.
• The new corporate structure will be centralized management (to be named Leading Primary Care, Inc.) with three operating subsidiaries: Live Well Medical Group, The Good Clinic Properties, Inc., and Live Well Drugstore, Inc.
• The company has entered into a definitive purchase agreement to acquire Pointe Medical Services, Inc., Pointe Med Pharmacy, Inc., Livewell MD, LLC, and Livewell Drugstore, LLC (collectively 'Pointe Med Pharmacy') for $15.8 million, payable in cash, debt assumption/payoff, stock issuance, earn-out, and performance bonus.
• An asset purchase agreement has been signed to acquire the physical and intangible assets of The Good Clinic, Inc. for $3.5 million in an all-stock deal.
• A firm commitment public offering is planned for up to 2,400,000 shares of Series D Convertible Preferred Stock and warrants to purchase up to 2,400,000 shares of Series D Convertible Preferred Stock, aiming to raise gross proceeds of $12 million.
• Net proceeds from the offering are expected to be $10,640,000, or $12,296,000 if the over-allotment option is exercised in full.
• Proceeds will be allocated to acquisitions ($9,000,000), hiring key personnel ($400,000), working capital and general corporate purposes ($740,000 $2,396,000), and marketing expenses ($500,000).
• The company intends to uplist its common stock to the NYSE under the symbol FCHS, contingent on raising at least $10.0 million.
• A 1-for-2,000 reverse stock split of the 32,958,288 common shares outstanding as of January 16, 2026, will be effected immediately after the registration statement's effectiveness but prior to NYSE listing. This reverse split does not apply to shares from the IPO, resale shares, or shares related to the Pointe Med/LiveWell and The Good Clinic acquisitions.
• First Choice Healthcare Solutions, Inc. (FCHS) reported net losses of $3.5 million for the nine months ended September 30, 2025, and $3.8 million for the year ended December 31, 2024.
• FCHS had an accumulated deficit of $71.3 million as of September 30, 2025, and $67.8 million as of December 31, 2024.
• Pointe Med/LiveWell (the acquired entity) reported net income attributable to shareholders of $1,444,050 for the nine months ended September 30, 2025, and $1,414,493 for the year ended December 31, 2024.

Sentiment

Score: 3

Explanation: While the strategic pivot into a growing healthcare segment and the acquisition of profitable entities are positive, the company's significant historical losses, accumulated deficit, and explicit 'going concern' warning for FCHS present substantial financial risks. The pro forma combined entity still shows losses, and the success of the capital raise and integration of new businesses is critical but uncertain. The high dilution potential and regulatory complexities further increase the speculative nature of this investment.

Positives

• The company is undertaking a strategic pivot into the high-growth primary care and wellness market, which is projected to expand significantly.
• The acquisitions of Pointe Med Pharmacy group and The Good Clinic bring existing operations and intellectual property, including a compounding pharmacy, which reported positive net income and cash flow from operations.
• The strategy leverages Nurse Practitioners, offering an estimated 25% labor cost advantage over traditional physician-staffed offices while studies suggest comparable or better care quality.
• The integration of a compounding pharmacy is expected to provide personalized medications and higher profit margins through consolidated overhead and operating expenses.
• A centralized administrative infrastructure is designed to achieve economies of scale and cost efficiencies as the network of clinics expands.
• The business model includes a robust suite of primary care services typically reimbursed by commercial and governmental insurance programs, ensuring a stable revenue base.
• The offering of quality-of-life services (e.g., anti-aging, weight management, hormone replacement, biohacking) primarily on a self-pay model provides additional, potentially high-margin revenue streams.
• The company utilizes a cloud-based Electronic Medical Record (EMR) system that complies with Meaningful Use standards, enhancing care coordination and reducing information system hazards.

Negatives

• First Choice Healthcare Solutions, Inc. (FCHS) has a history of significant net losses, with an accumulated deficit of $71.3 million as of September 30, 2025, and $67.8 million as of December 31, 2024.
• FCHS has experienced recurring cash outflows from operations, totaling $0.55 million for the nine months ended September 30, 2025, and $1.7 million for the year ended December 31, 2024.
• There is substantial doubt about FCHS's ability to continue as a going concern without securing additional capital.
• The company carries a high level of indebtedness, with total liabilities of $40,155,246 as of September 30, 2025.
• The public offering and conversion features of the Series D Convertible Preferred Stock and warrants will result in substantial dilution for existing stockholders.
• The success of the NYSE listing application is not assured, which is a condition for the offering and acquisitions to close.
• The reliance on a self-pay model for 15% of projected clinic revenue introduces risks of revenue volatility, bad debt, and pricing challenges.
• The company faces difficulties in integrating the acquired businesses and effectively managing growth in multiple new markets.
• The company's reputation has been tarnished by the criminal charges and guilty plea of its former Chief Executive Officer, Christian C. Romandetti, Sr., and subsequent bankruptcy proceedings.
• Prior to the offering, a significant percentage of the company's common stock and Series A Super Voting Preferred Stock is held by a small number of shareholders, potentially influencing corporate control.

Risks

• The company has posted minimal profit since commencing operations and has a history of net losses and accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
• Insufficient cash from operations may lead to liquidity problems, forcing the company to reduce or delay investments, dispose of assets, or seek additional financing, which may not be available on favorable terms or at all.
• Raising additional capital through equity or convertible debt securities will dilute existing ownership interests and may include liquidation preferences or restrictive covenants.
• The strategy to open new clinics in multiple markets makes it difficult to evaluate future business prospects and may strain resources, leading to operating inefficiencies or a deterioration in service quality.
• Changes in tax laws and unanticipated tax liabilities could adversely affect the effective income tax rate and ability to achieve profitability.
• Quarterly financial results are expected to fluctuate significantly due to factors like demand for services, client retention, economic conditions, and marketing costs.
• Volatility in financial markets could make future financing difficult or more expensive, adversely affecting the business.
• Potential profit margins may decline due to increasing pricing pressure in the healthcare industry.
• High indebtedness could require a substantial portion of cash flows for debt service, reduce financial flexibility, and expose the company to increased interest rates.
• Pandemics, epidemics, natural disasters, terrorist activities, and political unrest could have a material adverse impact on business operations, patient acquisition, and financial results.
• The company has a limited operating history in primary care clinics, making it difficult to evaluate future performance and requiring significant marketing investment to build patient panels.
• Acquisitions involve risks such as difficulties in integration, failure to achieve anticipated benefits, increased costs, diversion of management time, and challenges in maintaining effective internal controls.
• Inability to attract and retain qualified medical professionals, particularly Nurse Practitioners, could negatively affect operations, patient attraction, and the ability to open new clinics.
• Difficulties in managing company growth could lead to higher operating losses or prevent growth altogether, dependent on capital, employee management, and system improvements.
• Loss of key executives and failure to attract qualified managers could limit growth and negatively impact operations.
• The company may be subject to medical professional liability risks, which could be costly to defend and divert management attention.
• Billing Medicare, Medicaid, and TriCare programs, as well as commercial payers, presents significant compliance risks, fraud and abuse allegations, payment delays, audit risks, and the need to adapt to evolving regulations across multiple states.
• The healthcare regulatory and political framework is evolving, and significant changes could adversely affect financial condition and results of operations.
• The practice of pharmacy is highly regulated, and failure to comply with state and federal laws could limit the growth of compounding pharmacy revenue.
• Compounding pharmacies are dependent on the consistent availability and quality of base pharmaceuticals, and supply chain disruptions could significantly decrease revenue and service scope.
• Federal and state laws protecting the privacy and security of protected health information (HIPAA, HITECH) may increase costs and limit data use, subjecting the company to penalties for non-compliance.
• The quality of life services, based primarily on the self-pay model, could lead to fewer patients or the need for discounts, limiting growth and negatively impacting financial projections due to revenue volatility, bad debt, and pricing challenges.
• Changes in third-party reimbursement rates or methods for medical services could reduce demand or create downward pricing pressure, harming financial position.
• Federal and state restrictions on advertising may adversely affect the ability to market clinics and services.
• Reliance on information technology means any failure, inadequacy, interruption, or security lapse (including cybersecurity incidents) could harm business operations.
• The market for healthcare services is highly competitive, with numerous direct and indirect competitors having greater resources, potentially leading to price competition and reduced demand.
• A decline in consumer disposable income could adversely affect the number of clinical visits and negatively impact financial results, increasing bad debt.
• As a smaller reporting company, reduced disclosure requirements may make common stock less attractive to investors, leading to a less active trading market and more volatile stock price.
• The requirements of being a public company may strain resources and distract management, particularly after no longer being an emerging growth company.
• Management has broad discretion in the use of net proceeds from the offering, and ineffective use could harm the business.
• There has been a limited trading market for common stock, and an active market may not develop, impairing liquidity and capital raising ability.
• The market for common stock may fluctuate significantly due to various factors, including changes in government regulation, reimbursement policies, operating results, and loss of key personnel.
• The issuance of common stock upon conversion of preferred stock and exercise of warrants could cause substantial dilution, materially affecting the trading price.
• Resales by selling stockholders under the Resale Prospectus may have an adverse effect on the market price of common stock.
• The company has not paid dividends in the past and has no immediate plans to do so, meaning investors should not expect cash dividends.
• Quarterly operating results are expected to fluctuate, which could cause the stock price to decline.
• Penny stock rules may make buying or selling securities difficult, limiting liquidity.
• The former CEO's criminal charges have tarnished the company's reputation.
• Charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.
• Failure to achieve and maintain internal controls in accordance with Sections 302 and 404 of the Sarbanes-Oxley Act of 2002 could harm the business and stock price.

Future Outlook

The company expects to commence operations for its primary care and wellness clinics by March 1, 2026. It plans to expand into 27 states and the District of Columbia that allow Nurse Practitioners full practice authority, with an initial focus on northeast and southwest Florida and Minnesota for 2025 and 2026, and evaluating Denver and Phoenix for potential future expansion. The strategic plan anticipates achieving measurable cost and productivity efficiencies through a scalable, centralized administrative infrastructure, aiming to sustain profit margins as the network of clinics grows.

Management Comments

• Our go forward strategy will be executed using a corporate structure of centralized management services designated as Leading Primary Care, Inc. (which will be the Companys name after the proposed name change from First Choice Healthcare Solutions, Inc.) with three operating subsidiaries, Live Well Medical Group (comprised of the primary care clinic locations nationally), The Good Clinic Properties, Inc. (which holds leases on all physical clinic locations), and Live Well Drugstore, Inc. (comprised of our current and future compounding pharmacy operations).
• We believe our strategy of combining a full suite of primary care services and the specialized services of our competition in an operational environment focused on providing high quality care, excellent customer experience, personalized care plans and personalized medications has the potential to deliver our desired financial performance.
• The lower labor costs of employing Nurse Practitioners provide an approximate 25% margin improvement over the traditional primary care offices staffed with medical doctors. Additionally, studies prove Nurse Practitioners deliver care equal to and in some measures better than their physician counterparts.
• It is our plan that the cost of our back-office operations will not increase in direct relation to the growth of our network of primary care clinics, which will allow us to sustain profit margins across our business operations with a cost effective and scalable back office.

Industry Context

The U.S. healthcare market is substantial, with expenditures reaching $4.5 trillion in 2022 (17.3% of GDP) and projected to grow to $7.1 trillion (19.6% of GDP) by 2031. This growth, coupled with concerns about healthcare affordability and quality, drives a widespread call for investment in primary care. The market for healthcare solutions, including primary care clinics, online medical providers, and compounding pharmacies, is highly competitive and fragmented. The company aims to differentiate itself by offering personalized care and combining primary care with specialized quality-of-life services and an internal compounding pharmacy, competing against established virtual and brick-and-mortar players.

Comparison to Industry Standards

• The company's strategy to utilize Nurse Practitioners is expected to provide an approximate 25% labor cost advantage over traditional primary care offices staffed with medical doctors, with studies indicating Nurse Practitioners deliver care equal to or better than physicians.
• The U.S. primary care market, valued at $271.0 billion in 2023, is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.36% from 2024 to 2030, indicating a significant market opportunity for the company's pivot.
• The pharmaceutical weight loss market, valued at $6 billion in 2023, is projected to grow to $100 billion by 2030, aligning with the company's planned quality-of-life services.
• The Hormone Replacement Therapy (HRT) market, valued at $6.9 billion in 2022, is expected to grow to $13.4 billion by 2032, supporting the company's specialized offerings.
• The US peptides market, valued at $17.8 billion in 2022, is expected to grow at a CAGR of 7.0% from 2023 to 2030, presenting another growth area for personalized medications.
• The regenerative medicine US market, estimated at $16.8 billion in 2023, is projected to grow at a CAGR of 16.72% from 2024 to 2030, indicating strong demand for advanced treatment options.
• The biohacking market, estimated at $23.9 billion in 2023, is projected to grow at a CAGR of 19.48% to $67.9 billion by 2032, aligning with the company's focus on optimizing health and lifespan.

Management Changes

Corporate Governance

Legal Proceedings

• The company filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on June 15, 2020, and emerged from bankruptcy on April 27, 2022, with a confirmed reorganization plan.
• The company's reputation has been tarnished by the criminal charges and guilty plea of its former Chief Executive Officer, Christian C. Romandetti, Sr., for conspiracy to commit securities fraud.
• An outstanding accounts payable liability of approximately $1,200,000 remains from a lease settlement order received in October 2021, with ongoing efforts to reach a settlement with the landlord.
• A $19,473 judgment granted on January 25, 2024, in favor of an equipment lessor was subsequently settled for $9,000 in March 2024.
• A complaint from GMR Melbourne, LLC for breach of contract claiming $1,455,095 was settled via a court order in October 2021 for $1,443,498, with approximately $1,200,000 still unpaid as of December 31, 2024.
• A complaint filed by Coastal Neurology, Inc. seeking $100,000 in damages was withdrawn in 2024.
• A motion for summary judgment was granted on December 12, 2023, for MBABJB Holdings Family Limited Partnership for $102,884, including attorney fees and costs, due to lease payment defaults.
• Legal fees of $203,115 remain unpaid to Ackerman, LLP from bankruptcy proceedings, for which a motion for summary judgment was granted.
• The company has been involved in several employment-related matters, primarily due to unpaid wages following staff reductions and terminations, with the majority of cases having been settled.

Related Party Transactions

• Notes payable include $2,142,105 due to the company's Chief Executive Officer and $151,858 due to the prior Chief Financial Officer as of September 30, 2025, related to deferred compensation, payments to third-party service providers, and other normal course of business items.
• The Pointe Medical Live Well group leases space under an operating lease agreement dated October 1, 2019, with Live Well Realty, LLC, which is a related party.
• The company expects to adopt a written related party transactions policy requiring audit committee approval for transactions exceeding the lesser of $120,000 or one percent of the average of total assets for the last two completed fiscal years.

Stakeholder Impact

• Shareholders face significant dilution from the public offering and the anti-dilution provisions of the Series D Convertible Preferred Stock, with a potential for increased share price volatility and risk of total investment loss.
• Employees in legacy orthopedic and physical therapy services will be impacted by the termination of these services, while new opportunities will arise for Nurse Practitioners and administrative staff in the primary care and wellness clinics.
• Customers and patients will experience a shift to a personalized primary care and wellness model, including self-pay options for certain services, with the potential for enhanced care experiences and outcomes.
• Creditors will see certain existing liabilities settled or exchanged for Series C Preferred Stock, and the new capital raise is intended to fund operations and acquisitions, potentially improving the company's financial stability.
• Suppliers of base pharmaceuticals for the compounding pharmacy are critical to the new strategy, and any disruptions could impact the company's ability to deliver personalized medications and quality-of-life services.

Next Steps

• Complete the public offering of Series D Convertible Preferred Stock and warrants.
• Uplist common stock to the NYSE.
• Effect a 1-for-2,000 reverse stock split immediately after the registration statement's effectiveness but prior to NYSE listing.
• Complete the acquisition of Pointe Med Pharmacy group for $15.8 million.
• Complete the asset acquisition of The Good Clinic, Inc. for $3.5 million.
• Commence operations for the primary care and wellness clinics by March 1, 2026.
• Expand compounding pharmacy operations by increasing state licensures and seeking FDA 503B pharmacy accreditation.
• Identify and appoint new board members to fill the full board of directors upon completion of the offering.
• Re-establish the Audit, Nominating and Governance, and Compensation Committees in the third quarter of 2025.
• Evaluate Denver and Phoenix markets for potential future expansion opportunities.
• Pursue opening a total of thirty new clinics in the next four years as additional capital becomes available.

Key Dates

Recommendation

The company presents a highly speculative investment with significant inherent risks. While the strategic pivot into the growing primary care and wellness market, coupled with the acquisition of profitable entities, offers a potential path to growth, First Choice Healthcare Solutions, Inc. (FCHS) has a history of substantial net losses and an accumulated deficit, leading to an explicit 'going concern' warning. The pro forma combined financial statements, even after accounting for the acquisitions and capital raise, still project net losses. The public offering introduces significant dilution for existing shareholders, and the anti-dilution provisions of the Series D Preferred Stock could lead to further dilution. The company faces numerous operational and regulatory challenges in its new business model, including intense competition, reliance on a self-pay model for a portion of revenue, and the complexities of multi-state healthcare regulations. The success of the strategic pivot and the ability to achieve sustained profitability are highly uncertain and dependent on future capital raises and effective execution, which has been a challenge historically. The stock is also subject to penny stock rules, further limiting liquidity and investor interest. Given the high degree of risk, historical underperformance, and significant uncertainties, a seasoned investor would likely recommend selling or avoiding this stock.

Keywords

Healthcare, Primary Care, Wellness Clinics, Compounding Pharmacy, SEC Filing, S-1/A, Convertible Notes, Warrants, IPO, NYSE Listing, Medical Equipment, Anti-aging, Weight Management, Hormone Replacement Therapy, Biohacking, Nurse Practitioners, Financial Reporting, Risk Factors, Acquisitions, Dilution, Corporate Governance, Bankruptcy